Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial

被引:236
作者
Solomon, Scott R. [1 ]
Sizemore, Connie A. [1 ]
Sanacore, Melissa [1 ]
Zhang, Xu [2 ]
Brown, Stacey [1 ]
Holland, H. Kent [1 ]
Morris, Lawrence E. [1 ]
Bashey, Asad [1 ]
机构
[1] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA
[2] Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA
关键词
Haploidentical; Myeloablative; Allogeneic; Peripheral blood stem cell; TOTAL-BODY IRRADIATION; BONE-MARROW-TRANSPLANTATION; HLA-IDENTICAL SIBLINGS; VERSUS-HOST-DISEASE; HEMORRHAGIC CYSTITIS; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; REGIMEN INTENSITY; ACUTE-LEUKEMIA; RECIPIENTS; BUSULFAN;
D O I
10.1016/j.bbmt.2012.06.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haploidentical hematopoietic stem cell transplant (HSCT) provides an opportunity for nearly all patients to benefit from HSCT. We conducted a trial of haploidentical T cell replete allografting using a busulfan-based myeloablative preparative regimen, peripheral blood stem cells (PBSCs) as the graft source, and posttransplantation cyclophosphamide (Cy). Eligibility was limited to patients at high risk of relapse after nonmyeloablative haploidentical bone marrow transplant (BMT). Twenty patients were enrolled in the study (11 with relapsed/refractory disease and 9 who underwent transplantation while in remission and considered standard risk). Donor engraftment occurred in all 20 patients with full donor T cell and myeloid chimerism by day +30. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (aGVHD) was 30% and 10%, respectively. The cumulative incidence of chronic GVHD (cGVHD) was 35%. Nonrelapse mortality (NRM) at 100 days and 1 year was 10% for all patients and 0% for standard-risk patients. With a median follow-up of 20 months, the estimated 1-year overall survival (OS) and disease-free survival (DFS) was 69% and 50%, respectively, for all patients, and 88% and 67% for standard-risk patients. Myeloablative haploidentical HSCT is associated with excellent rates of engraftment, GVHD, NRM, and DFS, and is a valid option in patients with high-risk malignancies who lack timely access to a conventional donor. Biol Blood Marrow Transplant 18: 1859-1866 (2012) (c) 2012 American Society for Blood and Marrow Transplantation
引用
收藏
页码:1859 / 1866
页数:8
相关论文
共 26 条
[21]   DRUG-INDUCED IMMUNOLOGICAL TOLERANCE [J].
SCHWARTZ, R ;
DAMESHEK, W .
NATURE, 1959, 183 (4676) :1682-1683
[22]   Risk factors for severe hemorrhagic cystitis following BMT [J].
Seber, A ;
Shu, XO ;
Defor, T ;
Sencer, S ;
Ramsay, N .
BONE MARROW TRANSPLANTATION, 1999, 23 (01) :35-40
[23]   Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type [J].
Silva, Leandro de Padua ;
Patah, Poliana A. ;
Saliba, Rima M. ;
Szewczyk, Nicholas A. ;
Gilman, Lisa ;
Neumann, Joyce ;
Han, Xiang-Yang ;
Tarrand, Jeffrey ;
Ribeiro, Rachel ;
Gulbis, Alison ;
Shpall, Elizabeth J. ;
Jones, Roy ;
Popat, Uday ;
Walker, Julia A. ;
Petropoulos, Demetrios ;
Chiattone, Alexandre ;
Stewart, John ;
El-Zimaity, Maha ;
Anderlini, Paolo ;
Giralt, Sergio ;
Champlin, Richard E. ;
de Lima, Marcos .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (07) :1183-1190
[24]   Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings [J].
Szydlo, R ;
Goldman, JM ;
Klein, JP ;
Gale, RP ;
Ash, RC ;
Bach, FH ;
Bradley, BA ;
Casper, JT ;
Flomenberg, N ;
Gajewski, JL ;
Gluckman, E ;
HensleeDowney, PJ ;
Hows, JM ;
Jacobsen, N ;
Kolb, HJ ;
Lowenberg, B ;
Masaoka, T ;
Rowlings, PA ;
Sondel, PM ;
vanBekkum, DW ;
vanRood, JJ ;
Vowels, MR ;
Zhang, MJ ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1767-1777
[25]   Haemorrhagic cystitis: Incidence and risk factors in a transplant population using hyperhydration [J].
Trotman, J ;
Nivison-Smith, I ;
Dodds, A .
BONE MARROW TRANSPLANTATION, 1999, 23 (08) :797-801
[26]   The Role of Different Risk Factors in Clinical Presentation of Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplant Recipients [J].
Yaghobi, R. ;
Ramzi, M. ;
Dehghani, S. .
TRANSPLANTATION PROCEEDINGS, 2009, 41 (07) :2900-2902